董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bradford E. Bernstein | 男 | Director | 56 | 未披露 | 未持股 | 2023-04-26 |
| Kathleen Traynor DeRose | 女 | Director | 62 | 24.48万美元 | 未持股 | 2023-04-26 |
| Jan R. Hauser | 女 | Director | 63 | 18.99万美元 | 未持股 | 2023-04-26 |
| Lawrence Leibowitz | 男 | Director | 63 | 18.29万美元 | 未持股 | 2023-04-26 |
| Roy Luo | 男 | Director | 34 | 未披露 | 未持股 | 2023-04-26 |
| Oleg Movchan | 男 | Chief Executive Officer and Director | 50 | 165.70万美元 | 未持股 | 2023-04-26 |
| Michael Spellacy | 男 | Chair and Director | 51 | 未披露 | 未持股 | 2023-04-26 |
| Deirdre Somers | 女 | Director | 56 | 未披露 | 未持股 | 2023-04-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bradley Herring | 男 | Chief Financial Officer | 53 | 179.30万美元 | 未持股 | 2023-04-26 |
| Oleg Movchan | 男 | Chief Executive Officer and Director | 50 | 165.70万美元 | 未持股 | 2023-04-26 |
| Dan Groman | 男 | Chief Technology Officer | 35 | 未披露 | 未持股 | 2023-04-26 |
| Bradley Herring | 男 | Chief Financial Officer | 53 | 未披露 | 未持股 | 2023-04-26 |
| Bronwen Bastone | 女 | Chief People Officer | 50 | 186.48万美元 | 未持股 | 2023-04-26 |
董事简历
中英对照 | 中文 | 英文- Bradford E. Bernstein
-
Bradford E.Bernstein自2021年以来一直是我们董事会的成员，也是Enfusion Ltd.的董事会成员。自2016年12月起担任LLC。Bernstein先生从2003年开始担任FTV Capital的管理合伙人。Bernstein先生拥有超过30年的私人股本经验。任职FTV Capital公司之前，他曾担任Oak Hill Capital Management公司及其前身公司的合伙人，在那里他曾管理业务和金融服务集团。他在Patricof&Company Ventures开始了他的私人股本职业生涯，并在纽约Merrill Lynch的投资银行部门开始了他的职业生涯。Bernstein先生在塔夫茨大学以优异成绩获得学士学位。
Bradford E. Bernstein,has been a member of Enfusion, Inc. Board since 2021 and a member of the board of managers of Enfusion Ltd. LLC since December 2016. Mr. Bernstein has served as the managing partner of FTV Capital since 2003. Mr. Bernstein has over 30 years of private equity experience. Prior to FTV Capital, Mr. Bernstein was a partner at Oak Hill Capital Management and its predecessors where he managed the business and financial services group. He began his private equity career with Patricof & Company Ventures and started his professional career in the investment banking division of Merrill Lynch in New York. Mr. Bernstein received a B.A. magna cum laude from Tufts University. - Bradford E.Bernstein自2021年以来一直是我们董事会的成员，也是Enfusion Ltd.的董事会成员。自2016年12月起担任LLC。Bernstein先生从2003年开始担任FTV Capital的管理合伙人。Bernstein先生拥有超过30年的私人股本经验。任职FTV Capital公司之前，他曾担任Oak Hill Capital Management公司及其前身公司的合伙人，在那里他曾管理业务和金融服务集团。他在Patricof&Company Ventures开始了他的私人股本职业生涯，并在纽约Merrill Lynch的投资银行部门开始了他的职业生涯。Bernstein先生在塔夫茨大学以优异成绩获得学士学位。
- Bradford E. Bernstein,has been a member of Enfusion, Inc. Board since 2021 and a member of the board of managers of Enfusion Ltd. LLC since December 2016. Mr. Bernstein has served as the managing partner of FTV Capital since 2003. Mr. Bernstein has over 30 years of private equity experience. Prior to FTV Capital, Mr. Bernstein was a partner at Oak Hill Capital Management and its predecessors where he managed the business and financial services group. He began his private equity career with Patricof & Company Ventures and started his professional career in the investment banking division of Merrill Lynch in New York. Mr. Bernstein received a B.A. magna cum laude from Tufts University.
- Kathleen Traynor DeRose
-
Kathleen Traynor Derose自2021年以来一直是我们董事会的成员。DeRose女士目前是纽约大学斯特恩商学院的临床金融学副教授，富邦科技，商业和创新中心主任，自2016年9月以来一直在那里工作。她也是Voya Financial Company和the London Stock Exchange Group的董事会成员。此前，她曾担任Credit Suisse Group Ag（位于瑞士苏黎世）的董事总经理。在加入瑞士信贷之前，Derose女士是投资咨询公司Hagin Investment Management Inc.的高级管理合伙人兼投资组合管理和研究主管。Derose女士拥有牛津大学当代中国研究硕士学位，纽约大学斯特恩商学院Trium项目的工商管理硕士学位和普林斯顿大学的美国历史学士学位。
Kathleen Traynor DeRose,has been a member of Enfusion, Inc. Board since 2021. Ms. DeRose is currently a clinical associate professor of finance and the director of the Fubon Center for Technology, Business, and Innovation at New York University's Stern School of Business, where she has been since September 2016. She also sits on the boards of Experian plc, Voya Financial Company and the London Stock Exchange Group. Previously, she was a managing director at Credit Suisse Group AG in Zurich, Switzerland. Prior to Credit Suisse, Ms. DeRose was a senior managing partner and the head of portfolio management and research at Hagin Investment Management Inc, an investment advisory firm. Ms. DeRose holds a MSc in Contemporary Chinese Studies from the University of Oxford, an MBA from New York University – Stern School of Business (TRIUM program) and a BA in American History from Princeton University. - Kathleen Traynor Derose自2021年以来一直是我们董事会的成员。DeRose女士目前是纽约大学斯特恩商学院的临床金融学副教授，富邦科技，商业和创新中心主任，自2016年9月以来一直在那里工作。她也是Voya Financial Company和the London Stock Exchange Group的董事会成员。此前，她曾担任Credit Suisse Group Ag（位于瑞士苏黎世）的董事总经理。在加入瑞士信贷之前，Derose女士是投资咨询公司Hagin Investment Management Inc.的高级管理合伙人兼投资组合管理和研究主管。Derose女士拥有牛津大学当代中国研究硕士学位，纽约大学斯特恩商学院Trium项目的工商管理硕士学位和普林斯顿大学的美国历史学士学位。
- Kathleen Traynor DeRose,has been a member of Enfusion, Inc. Board since 2021. Ms. DeRose is currently a clinical associate professor of finance and the director of the Fubon Center for Technology, Business, and Innovation at New York University's Stern School of Business, where she has been since September 2016. She also sits on the boards of Experian plc, Voya Financial Company and the London Stock Exchange Group. Previously, she was a managing director at Credit Suisse Group AG in Zurich, Switzerland. Prior to Credit Suisse, Ms. DeRose was a senior managing partner and the head of portfolio management and research at Hagin Investment Management Inc, an investment advisory firm. Ms. DeRose holds a MSc in Contemporary Chinese Studies from the University of Oxford, an MBA from New York University – Stern School of Business (TRIUM program) and a BA in American History from Princeton University.
- Jan R. Hauser
-
Jan R. Hauser，在2022年6月加入了Proterra董事会。Hauser女士曾在通用电气（General Electric）担任副总裁兼首席会计官，通用电气是一家美国跨国综合企业，涉足电力和可再生能源等领域。她在通用电气工作期间，领导了一个拥有3，000多名专业人员的全球财务控制团队，并于2019年初从通用电气退休。在加入通用电气之前，Hauser女士曾是普华永道（PriceWaterhouseCoopers LLP）国家办公室的高级咨询合伙人，负责多个领域的技术支持工作。她曾担任Vonage董事会成员，并在2019年至2022年期间担任审计委员会主席。她领导了普华永道国家办公室的多元化工作，并在普华永道的美国合伙人录取委员会任职。Hauser女士曾代表普华永道参与财务会计准则委员会的新兴问题工作组和财务会计准则咨询委员会。自2021年9月以来，Hauser女士一直担任Enfusion, Inc.的董事会成员。她是持有注册会计师执照的执业会计师，并拥有威斯康星大学惠特沃特分校的工商管理学士学位（会计专业）。
Jan R. Hauser,has been a member of Enfusion, Inc. Board since 2021. She is a certified public accountant with over 35 years of experience navigating complex business transactions and strategies. Ms. Hauser currently sits on the board of directors of Magna International Inc. and Proterra Inc., where she also serves on the Audit Committee. She previously served on the board of Vonage Holdings Corp., including as Audit Committee Chair from June 2020 to July 2022. From 2013 until 2019, Ms. Hauser served in various capacities, including as Vice President, Chief Accounting Officer, and Controller, at the General Electric Company. Prior to GE, Ms. Hauser was a Partner in the National Office of PricewaterhouseCoopers LLP, serving as a senior technical resource on multiple topics. In addition, she led diversity efforts for the National Office and served on the U.S. Partner Admissions Committee. Early in her career, Ms. Hauser was selected for a two-year fellowship in the Office of the Chief Accountant at the SEC. Ms. Hauser holds a Bachelor of Business Administration, Accounting, summa cum laude, from the University of Wisconsin–Whitewater. - Jan R. Hauser，在2022年6月加入了Proterra董事会。Hauser女士曾在通用电气（General Electric）担任副总裁兼首席会计官，通用电气是一家美国跨国综合企业，涉足电力和可再生能源等领域。她在通用电气工作期间，领导了一个拥有3，000多名专业人员的全球财务控制团队，并于2019年初从通用电气退休。在加入通用电气之前，Hauser女士曾是普华永道（PriceWaterhouseCoopers LLP）国家办公室的高级咨询合伙人，负责多个领域的技术支持工作。她曾担任Vonage董事会成员，并在2019年至2022年期间担任审计委员会主席。她领导了普华永道国家办公室的多元化工作，并在普华永道的美国合伙人录取委员会任职。Hauser女士曾代表普华永道参与财务会计准则委员会的新兴问题工作组和财务会计准则咨询委员会。自2021年9月以来，Hauser女士一直担任Enfusion, Inc.的董事会成员。她是持有注册会计师执照的执业会计师，并拥有威斯康星大学惠特沃特分校的工商管理学士学位（会计专业）。
- Jan R. Hauser,has been a member of Enfusion, Inc. Board since 2021. She is a certified public accountant with over 35 years of experience navigating complex business transactions and strategies. Ms. Hauser currently sits on the board of directors of Magna International Inc. and Proterra Inc., where she also serves on the Audit Committee. She previously served on the board of Vonage Holdings Corp., including as Audit Committee Chair from June 2020 to July 2022. From 2013 until 2019, Ms. Hauser served in various capacities, including as Vice President, Chief Accounting Officer, and Controller, at the General Electric Company. Prior to GE, Ms. Hauser was a Partner in the National Office of PricewaterhouseCoopers LLP, serving as a senior technical resource on multiple topics. In addition, she led diversity efforts for the National Office and served on the U.S. Partner Admissions Committee. Early in her career, Ms. Hauser was selected for a two-year fellowship in the Office of the Chief Accountant at the SEC. Ms. Hauser holds a Bachelor of Business Administration, Accounting, summa cum laude, from the University of Wisconsin–Whitewater.
- Lawrence Leibowitz
-
Lawrence Leibowitz自2021年以来一直是我们董事会的成员。Leibowitz先生是一位经验丰富的金融和技术企业家，专门从事业务转型和资本市场。他是Atlas Merchant Capital LLC的运营合伙人，并任职于Cowen，Inc.（一家独立投资银行）和Concord Acquisition Corp（一家特殊目的收购公司）的董事会，以及多种其他私人公司的董事会。Leibowitz先生从2007年到2013年担任纽约泛欧交易所集团的首席运营官，全球股票市场主管和董事会成员。
Lawrence Leibowitz,has been a member of Enfusion, Inc. Board since 2021. Mr. Leibowitz is an experienced finance and technology entrepreneur who specializes in business transformation and capital markets. He is an Operating Partner of Atlas Merchant Capital LLC and serves on the board of directors of Cowen, Inc., an independent investment bank, and Concord Acquisition Corp, a special purpose acquisition company, as well as on the board of various other private companies. Mr. Leibowitz served as Chief Operating Officer, Head of Global Equities Markets and as a Member of the board of directors of NYSE Euronext, from 2007 to 2013. - Lawrence Leibowitz自2021年以来一直是我们董事会的成员。Leibowitz先生是一位经验丰富的金融和技术企业家，专门从事业务转型和资本市场。他是Atlas Merchant Capital LLC的运营合伙人，并任职于Cowen，Inc.（一家独立投资银行）和Concord Acquisition Corp（一家特殊目的收购公司）的董事会，以及多种其他私人公司的董事会。Leibowitz先生从2007年到2013年担任纽约泛欧交易所集团的首席运营官，全球股票市场主管和董事会成员。
- Lawrence Leibowitz,has been a member of Enfusion, Inc. Board since 2021. Mr. Leibowitz is an experienced finance and technology entrepreneur who specializes in business transformation and capital markets. He is an Operating Partner of Atlas Merchant Capital LLC and serves on the board of directors of Cowen, Inc., an independent investment bank, and Concord Acquisition Corp, a special purpose acquisition company, as well as on the board of various other private companies. Mr. Leibowitz served as Chief Operating Officer, Head of Global Equities Markets and as a Member of the board of directors of NYSE Euronext, from 2007 to 2013.
- Roy Luo
-
Roy Luo自2021年以来一直是我们的董事会成员，也是Enfusion Ltd.的董事会成员。自2020年12月起担任LLC。罗先生自2018年4月以来一直担任Iconiq Capital的投资者，此前曾于2015年2月至2018年3月担任Technology Crossover Ventures的投资者。罗先生拥有耶鲁大学的文学学士学位。
Roy Luo,has been a member of Enfusion, Inc. Board since 2021 and a member of the board of managers of Enfusion Ltd. LLC since December 2020. Mr. Luo has served as an investor at ICONIQ Capital since April 2018, and previously served as an investor at Technology Crossover Ventures ("TCV") from February 2015 until March 2018.Mr. Luo holds a B.S. from Yale University. - Roy Luo自2021年以来一直是我们的董事会成员，也是Enfusion Ltd.的董事会成员。自2020年12月起担任LLC。罗先生自2018年4月以来一直担任Iconiq Capital的投资者，此前曾于2015年2月至2018年3月担任Technology Crossover Ventures的投资者。罗先生拥有耶鲁大学的文学学士学位。
- Roy Luo,has been a member of Enfusion, Inc. Board since 2021 and a member of the board of managers of Enfusion Ltd. LLC since December 2020. Mr. Luo has served as an investor at ICONIQ Capital since April 2018, and previously served as an investor at Technology Crossover Ventures ("TCV") from February 2015 until March 2018.Mr. Luo holds a B.S. from Yale University.
- Oleg Movchan
-
Oleg Movchan自2021年以来一直是我们董事会的成员，也是Enfusion Ltd.的董事会成员。自2009年2月起担任LLC。他自2014年11月起担任Revolution Global的首席投资官，首席战略官和副首席执行官；自2018年11月起担任他创立的私募股权和风险投资公司Gimel Tech Ventures的管理合伙人；Quiet Light Partners的管理成员，自2021年5月以来，是一家专有的衍生品交易公司；自2013年4月以来，担任资产管理咨询公司Kameosa Capital，LLC的首席执行官，该公司提供有关业务和产品策略的综合咨询。Movchan先生毕业于宾夕法尼亚大学沃顿商学院的Aresty高管教育学院的综合管理课程，并拥有芝加哥大学的M.S.和M.B.A.以及哈尔科夫州立大学的M.S.。
Oleg Movchan,has been a member of Enfusion, Inc. Board since 2021, a member of the board of managers of Enfusion Ltd. LLC since February 2009, Enfusion, Inc. Interim Chief Executive Officer from August 2022 to December 2022, and Enfusion, Inc. Chief Executive Officer since December 2022. He has served as: the Chief Investment Officer, Chief Strategy Officer, and Deputy Chief Executive Officer of Revolution Global since November 2014; and the managing partner of Gimel Tech Ventures, a private equity and venture capital firm he founded, since November 2018; the managing member of Quiet Light Partners, a proprietary derivatives trading firm, since May 2021; and the Chief Executive Officer of Kameosa Capital, LLC, an asset management advisory firm which provides integrated advisory on business and product strategy, since April 2013. Mr. Movchan is a graduate of the General Management Program from the Aresty Institute of Executive Education at the Wharton School, University of Pennsylvania, and holds an M.S. and an M.B.A from the University of Chicago and an M.S. from Kharkov State University. - Oleg Movchan自2021年以来一直是我们董事会的成员，也是Enfusion Ltd.的董事会成员。自2009年2月起担任LLC。他自2014年11月起担任Revolution Global的首席投资官，首席战略官和副首席执行官；自2018年11月起担任他创立的私募股权和风险投资公司Gimel Tech Ventures的管理合伙人；Quiet Light Partners的管理成员，自2021年5月以来，是一家专有的衍生品交易公司；自2013年4月以来，担任资产管理咨询公司Kameosa Capital，LLC的首席执行官，该公司提供有关业务和产品策略的综合咨询。Movchan先生毕业于宾夕法尼亚大学沃顿商学院的Aresty高管教育学院的综合管理课程，并拥有芝加哥大学的M.S.和M.B.A.以及哈尔科夫州立大学的M.S.。
- Oleg Movchan,has been a member of Enfusion, Inc. Board since 2021, a member of the board of managers of Enfusion Ltd. LLC since February 2009, Enfusion, Inc. Interim Chief Executive Officer from August 2022 to December 2022, and Enfusion, Inc. Chief Executive Officer since December 2022. He has served as: the Chief Investment Officer, Chief Strategy Officer, and Deputy Chief Executive Officer of Revolution Global since November 2014; and the managing partner of Gimel Tech Ventures, a private equity and venture capital firm he founded, since November 2018; the managing member of Quiet Light Partners, a proprietary derivatives trading firm, since May 2021; and the Chief Executive Officer of Kameosa Capital, LLC, an asset management advisory firm which provides integrated advisory on business and product strategy, since April 2013. Mr. Movchan is a graduate of the General Management Program from the Aresty Institute of Executive Education at the Wharton School, University of Pennsylvania, and holds an M.S. and an M.B.A from the University of Chicago and an M.S. from Kharkov State University.
- Michael Spellacy
-
Michael Spellacy，自2023年以来一直是Enfusion, Inc.董事会成员。Spellacy先生于2020年10月被任命为Atlas Crest Investment Corp.的首席执行官兼董事。Spellacy先生还自2021年1月起担任Atlas Crest Investment Corp. II的首席执行官兼董事，并自2021年9月起担任Archer Aviation Inc.的董事。Spellacy先生在技术、数据和分析、资本市场和私募股权方面拥有丰富的经验，曾担任投资者、投资银行家和顾问。最近，Spellacy先生于2018年9月至2020年10月担任埃森哲公司（“埃森哲”）高级董事总经理，并于2017年12月至2018年8月担任埃森哲资本市场全球行业负责人，同时监督埃森哲的资产管理、财富管理以及投资和交易业务。Spellacy先生于2017年开始在埃森哲任职。在加入埃森哲之前，Spellacy先生曾于2015年至2017年在普华永道会计师事务所担任资产和财富管理高级合伙人。Spellacy先生拥有伦敦经济学院经济学理学学士学位和哈特福德大学MBA学位。
Michael Spellacy,has been a member of Enfusion, Inc. Board since 2023. Mr. Spellacy was appointed Atlas Crest Investment Corp.'s Chief Executive Officer and director in October of 2020. Mr. Spellacy has also been the Chief Executive Officer and a director of Atlas Crest Investment Corp. II since January 2021, and has been a director of Archer Aviation Inc. since September 2021. Mr. Spellacy has extensive experience in technology, data and analytics, capital markets and private equity and has worked as an investor, investment banker and consultant. Most recently, Mr. Spellacy was a Senior Managing Director at Accenture plc ("Accenture") from September 2018 to October 2020 and Global Industry Leader of Accenture Capital Markets from December 2017 to August 2018 while overseeing Accenture's Asset Management, Wealth Management and Investment and Trading businesses. Mr. Spellacy began his role at Accenture in 2017. Prior to Accenture, Mr. Spellacy was a Senior Partner, Asset and Wealth Management, at PricewaterhouseCoopers LLP from 2015 to 2017. Mr. Spellacy has a Bachelor of Science degree in Economics from the London School of Economics and an MBA from the University of Hartford. - Michael Spellacy，自2023年以来一直是Enfusion, Inc.董事会成员。Spellacy先生于2020年10月被任命为Atlas Crest Investment Corp.的首席执行官兼董事。Spellacy先生还自2021年1月起担任Atlas Crest Investment Corp. II的首席执行官兼董事，并自2021年9月起担任Archer Aviation Inc.的董事。Spellacy先生在技术、数据和分析、资本市场和私募股权方面拥有丰富的经验，曾担任投资者、投资银行家和顾问。最近，Spellacy先生于2018年9月至2020年10月担任埃森哲公司（“埃森哲”）高级董事总经理，并于2017年12月至2018年8月担任埃森哲资本市场全球行业负责人，同时监督埃森哲的资产管理、财富管理以及投资和交易业务。Spellacy先生于2017年开始在埃森哲任职。在加入埃森哲之前，Spellacy先生曾于2015年至2017年在普华永道会计师事务所担任资产和财富管理高级合伙人。Spellacy先生拥有伦敦经济学院经济学理学学士学位和哈特福德大学MBA学位。
- Michael Spellacy,has been a member of Enfusion, Inc. Board since 2023. Mr. Spellacy was appointed Atlas Crest Investment Corp.'s Chief Executive Officer and director in October of 2020. Mr. Spellacy has also been the Chief Executive Officer and a director of Atlas Crest Investment Corp. II since January 2021, and has been a director of Archer Aviation Inc. since September 2021. Mr. Spellacy has extensive experience in technology, data and analytics, capital markets and private equity and has worked as an investor, investment banker and consultant. Most recently, Mr. Spellacy was a Senior Managing Director at Accenture plc ("Accenture") from September 2018 to October 2020 and Global Industry Leader of Accenture Capital Markets from December 2017 to August 2018 while overseeing Accenture's Asset Management, Wealth Management and Investment and Trading businesses. Mr. Spellacy began his role at Accenture in 2017. Prior to Accenture, Mr. Spellacy was a Senior Partner, Asset and Wealth Management, at PricewaterhouseCoopers LLP from 2015 to 2017. Mr. Spellacy has a Bachelor of Science degree in Economics from the London School of Economics and an MBA from the University of Hartford.
- Deirdre Somers
-
Deirdre Somers，自2023年以来一直是Enfusion，Inc.董事会成员。Somers女士在市场、资产管理和投资基金方面拥有30多年的经验，曾于2007-2018年担任爱尔兰证券交易所（现为都柏林泛欧交易所）的首席执行官，并于1998-2007年担任上市总监。她在金融产品、市场结构、欧盟监管、企业行动和公共市场过渡方面拥有丰富的国际经验和行业知识。自2019年以来，她曾担任多家公共和私营公司和投资工具的独立非执行董事（“INED”），目前是Aquis Exchange PLC、贝莱德 iShares I-VII、Kenmare Resources plc和Episode Inc.的INED和委员会成员/主席，并担任爱尔兰癌症试验的主席。Somers女士拥有爱尔兰特许会计师协会的研究金和科克大学学院的商业学士学位。
Deirdre Somers,has been a member of Enfusion, Inc. board since 2023. Ms. Somers has more than 30 years of experience in markets, asset management and investment funds having served as CEO of the Irish Stock Exchange (now Euronext Dublin) from 2007-2018 and Director of Listing from 1998-2007. She has extensive international experience and industry knowledge in financial products, market structure, EU regulation, corporate actions and public market transitions. Since 2019, she has served as an independent, non executive director ("INED") of a number of companies and investment vehicles, both public and private, and she is currently an INED and committee member/chair of Aquis Exchange PLC, BlackRock iShares I-VII, Kenmare Resources plc, and Episode Inc., and chairs Cancer trials Ireland. Ms. Somers holds a Fellowship of the Institute of Chartered Accountants in Ireland and a Bachelor of Commerce degree from University College Cork. - Deirdre Somers，自2023年以来一直是Enfusion，Inc.董事会成员。Somers女士在市场、资产管理和投资基金方面拥有30多年的经验，曾于2007-2018年担任爱尔兰证券交易所（现为都柏林泛欧交易所）的首席执行官，并于1998-2007年担任上市总监。她在金融产品、市场结构、欧盟监管、企业行动和公共市场过渡方面拥有丰富的国际经验和行业知识。自2019年以来，她曾担任多家公共和私营公司和投资工具的独立非执行董事（“INED”），目前是Aquis Exchange PLC、贝莱德 iShares I-VII、Kenmare Resources plc和Episode Inc.的INED和委员会成员/主席，并担任爱尔兰癌症试验的主席。Somers女士拥有爱尔兰特许会计师协会的研究金和科克大学学院的商业学士学位。
- Deirdre Somers,has been a member of Enfusion, Inc. board since 2023. Ms. Somers has more than 30 years of experience in markets, asset management and investment funds having served as CEO of the Irish Stock Exchange (now Euronext Dublin) from 2007-2018 and Director of Listing from 1998-2007. She has extensive international experience and industry knowledge in financial products, market structure, EU regulation, corporate actions and public market transitions. Since 2019, she has served as an independent, non executive director ("INED") of a number of companies and investment vehicles, both public and private, and she is currently an INED and committee member/chair of Aquis Exchange PLC, BlackRock iShares I-VII, Kenmare Resources plc, and Episode Inc., and chairs Cancer trials Ireland. Ms. Somers holds a Fellowship of the Institute of Chartered Accountants in Ireland and a Bachelor of Commerce degree from University College Cork.
高管简历
中英对照 | 中文 | 英文- Bradley Herring
Bradley Herring自成立以来一直担任Shift4Payments，Inc.的首席财务官，自2019年10月起担任Shift4Payments，LLC的首席财务官。在2016年至2019年加入Shift4之前，Herring先生曾担任信用卡交易处理商Elavon，Inc.的首席财务官。2012年至2015年，Herring先生还担任在线银行和在线支付服务提供商Fiserv数字银行集团的首席财务官。他也曾担任Equifax公司的全球运营Vice President5年（2008年至2013年）。Herring先生通过了由金融业监管局（Financial Industry Regulatory Authority，Inc.）管理的Series7普通证券代表考试。他持有Georgia Institute of Technology Scheller College of Business的管理和经济学文学学士学位和工商管理硕士学位。
Bradley Herring,has been Enfusion, Inc. Chief Financial Officer since December 2022. Previously, Mr. Herring served as Chief Financial Officer of Shift4 Payments, a NYSE-listed payment processing and SaaS company, from October 2019 to August 2022, and as Chief Financial Officer of Elavon, Inc., a processor of credit card transactions from 2016 to 2019. Mr. Herring also served as Chief Financial Officer of the digital banking group of Fiserv, a provider of online banking and online payment services, from 2012 to 2015. He was also the Vice President of Global Operations for Equifax for five years, from 2008 to 2013. Mr. Herring has passed the Series 7 General Securities Representative Exam, administered by the Financial Industry Regulatory Authority, Inc. He holds a Bachelor of Arts degree in Management and Economics and a Master's of Business Administration from Georgia Institute of Technology Scheller College of Business.- Bradley Herring自成立以来一直担任Shift4Payments，Inc.的首席财务官，自2019年10月起担任Shift4Payments，LLC的首席财务官。在2016年至2019年加入Shift4之前，Herring先生曾担任信用卡交易处理商Elavon，Inc.的首席财务官。2012年至2015年，Herring先生还担任在线银行和在线支付服务提供商Fiserv数字银行集团的首席财务官。他也曾担任Equifax公司的全球运营Vice President5年（2008年至2013年）。Herring先生通过了由金融业监管局（Financial Industry Regulatory Authority，Inc.）管理的Series7普通证券代表考试。他持有Georgia Institute of Technology Scheller College of Business的管理和经济学文学学士学位和工商管理硕士学位。
- Bradley Herring,has been Enfusion, Inc. Chief Financial Officer since December 2022. Previously, Mr. Herring served as Chief Financial Officer of Shift4 Payments, a NYSE-listed payment processing and SaaS company, from October 2019 to August 2022, and as Chief Financial Officer of Elavon, Inc., a processor of credit card transactions from 2016 to 2019. Mr. Herring also served as Chief Financial Officer of the digital banking group of Fiserv, a provider of online banking and online payment services, from 2012 to 2015. He was also the Vice President of Global Operations for Equifax for five years, from 2008 to 2013. Mr. Herring has passed the Series 7 General Securities Representative Exam, administered by the Financial Industry Regulatory Authority, Inc. He holds a Bachelor of Arts degree in Management and Economics and a Master's of Business Administration from Georgia Institute of Technology Scheller College of Business.
- Oleg Movchan
Oleg Movchan自2021年以来一直是我们董事会的成员，也是Enfusion Ltd.的董事会成员。自2009年2月起担任LLC。他自2014年11月起担任Revolution Global的首席投资官，首席战略官和副首席执行官；自2018年11月起担任他创立的私募股权和风险投资公司Gimel Tech Ventures的管理合伙人；Quiet Light Partners的管理成员，自2021年5月以来，是一家专有的衍生品交易公司；自2013年4月以来，担任资产管理咨询公司Kameosa Capital，LLC的首席执行官，该公司提供有关业务和产品策略的综合咨询。Movchan先生毕业于宾夕法尼亚大学沃顿商学院的Aresty高管教育学院的综合管理课程，并拥有芝加哥大学的M.S.和M.B.A.以及哈尔科夫州立大学的M.S.。
Oleg Movchan,has been a member of Enfusion, Inc. Board since 2021, a member of the board of managers of Enfusion Ltd. LLC since February 2009, Enfusion, Inc. Interim Chief Executive Officer from August 2022 to December 2022, and Enfusion, Inc. Chief Executive Officer since December 2022. He has served as: the Chief Investment Officer, Chief Strategy Officer, and Deputy Chief Executive Officer of Revolution Global since November 2014; and the managing partner of Gimel Tech Ventures, a private equity and venture capital firm he founded, since November 2018; the managing member of Quiet Light Partners, a proprietary derivatives trading firm, since May 2021; and the Chief Executive Officer of Kameosa Capital, LLC, an asset management advisory firm which provides integrated advisory on business and product strategy, since April 2013. Mr. Movchan is a graduate of the General Management Program from the Aresty Institute of Executive Education at the Wharton School, University of Pennsylvania, and holds an M.S. and an M.B.A from the University of Chicago and an M.S. from Kharkov State University.- Oleg Movchan自2021年以来一直是我们董事会的成员，也是Enfusion Ltd.的董事会成员。自2009年2月起担任LLC。他自2014年11月起担任Revolution Global的首席投资官，首席战略官和副首席执行官；自2018年11月起担任他创立的私募股权和风险投资公司Gimel Tech Ventures的管理合伙人；Quiet Light Partners的管理成员，自2021年5月以来，是一家专有的衍生品交易公司；自2013年4月以来，担任资产管理咨询公司Kameosa Capital，LLC的首席执行官，该公司提供有关业务和产品策略的综合咨询。Movchan先生毕业于宾夕法尼亚大学沃顿商学院的Aresty高管教育学院的综合管理课程，并拥有芝加哥大学的M.S.和M.B.A.以及哈尔科夫州立大学的M.S.。
- Oleg Movchan,has been a member of Enfusion, Inc. Board since 2021, a member of the board of managers of Enfusion Ltd. LLC since February 2009, Enfusion, Inc. Interim Chief Executive Officer from August 2022 to December 2022, and Enfusion, Inc. Chief Executive Officer since December 2022. He has served as: the Chief Investment Officer, Chief Strategy Officer, and Deputy Chief Executive Officer of Revolution Global since November 2014; and the managing partner of Gimel Tech Ventures, a private equity and venture capital firm he founded, since November 2018; the managing member of Quiet Light Partners, a proprietary derivatives trading firm, since May 2021; and the Chief Executive Officer of Kameosa Capital, LLC, an asset management advisory firm which provides integrated advisory on business and product strategy, since April 2013. Mr. Movchan is a graduate of the General Management Program from the Aresty Institute of Executive Education at the Wharton School, University of Pennsylvania, and holds an M.S. and an M.B.A from the University of Chicago and an M.S. from Kharkov State University.
- Dan Groman
Dan Groman自2021年7月起担任我们的首席技术官。在此之前，Groman先生从2020年3月至2021年6月担任我们的技术主管，从2017年至2020年担任我们的高级开发协调员兼开发经理，并从2016年开始担任Enfusion的软件开发人员。Groman先生在德保罗大学获得计算机科学硕士学位，并在马里兰大学帕克分校获得学士学位。
Dan Groman,has been Enfusion, Inc. Chief Technology Officer since July 2021. Previously, Mr. Groman served as Enfusion, Inc. Head of Technology from March 2020 to June 2021, Enfusion, Inc. Senior Development Coordinator and Development Manager from 2017 to 2020 and has been a software developer at Enfusion starting in 2016. Mr. Groman holds an M.S. in Computer Science from DePaul University and a B.A. from the University of Maryland at College Park.- Dan Groman自2021年7月起担任我们的首席技术官。在此之前，Groman先生从2020年3月至2021年6月担任我们的技术主管，从2017年至2020年担任我们的高级开发协调员兼开发经理，并从2016年开始担任Enfusion的软件开发人员。Groman先生在德保罗大学获得计算机科学硕士学位，并在马里兰大学帕克分校获得学士学位。
- Dan Groman,has been Enfusion, Inc. Chief Technology Officer since July 2021. Previously, Mr. Groman served as Enfusion, Inc. Head of Technology from March 2020 to June 2021, Enfusion, Inc. Senior Development Coordinator and Development Manager from 2017 to 2020 and has been a software developer at Enfusion starting in 2016. Mr. Groman holds an M.S. in Computer Science from DePaul University and a B.A. from the University of Maryland at College Park.
- Bradley Herring
Bradley Herring，自2022年12月起担任Enfusion, Inc.TERM1，首席财务官。在此之前，Herring先生曾于2019年10月至2022年8月在纽交所上市的支付处理和SaaS公司Shift4 Payments担任首席财务官，并于2016年至2019年在Elavon，Inc.（一家信用卡交易处理商）担任首席财务官。Herring先生还于2012年至2015年担任网上银行和在线支付服务提供商费哲金融服务数字银行组的首席财务官。他还曾担任艾可菲全球运营副总裁五年，从2008年到2013年。Herring先生已通过Series 7 General Securities Representative Exam，由Financial Industry Regulatory Authority，Inc.管理。他拥有乔治亚理工学院谢勒商学院管理和经济学文学士学位和工商管理硕士学位。
Bradley Herring,has been Enfusion, Inc. Chief Financial Officer since December 2022. Previously, Mr. Herring served as Chief Financial Officer of Shift4 Payments, a NYSE-listed payment processing and SaaS company, from October 2019 to August 2022, and as Chief Financial Officer of Elavon, Inc., a processor of credit card transactions from 2016 to 2019. Mr. Herring also served as Chief Financial Officer of the digital banking group of Fiserv, a provider of online banking and online payment services, from 2012 to 2015. He was also the Vice President of Global Operations for Equifax for five years, from 2008 to 2013. Mr. Herring has passed the Series 7 General Securities Representative Exam, administered by the Financial Industry Regulatory Authority, Inc. He holds a Bachelor of Arts degree in Management and Economics and a Master's of Business Administration from Georgia Institute of Technology Scheller College of Business.- Bradley Herring，自2022年12月起担任Enfusion, Inc.TERM1，首席财务官。在此之前，Herring先生曾于2019年10月至2022年8月在纽交所上市的支付处理和SaaS公司Shift4 Payments担任首席财务官，并于2016年至2019年在Elavon，Inc.（一家信用卡交易处理商）担任首席财务官。Herring先生还于2012年至2015年担任网上银行和在线支付服务提供商费哲金融服务数字银行组的首席财务官。他还曾担任艾可菲全球运营副总裁五年，从2008年到2013年。Herring先生已通过Series 7 General Securities Representative Exam，由Financial Industry Regulatory Authority，Inc.管理。他拥有乔治亚理工学院谢勒商学院管理和经济学文学士学位和工商管理硕士学位。
- Bradley Herring,has been Enfusion, Inc. Chief Financial Officer since December 2022. Previously, Mr. Herring served as Chief Financial Officer of Shift4 Payments, a NYSE-listed payment processing and SaaS company, from October 2019 to August 2022, and as Chief Financial Officer of Elavon, Inc., a processor of credit card transactions from 2016 to 2019. Mr. Herring also served as Chief Financial Officer of the digital banking group of Fiserv, a provider of online banking and online payment services, from 2012 to 2015. He was also the Vice President of Global Operations for Equifax for five years, from 2008 to 2013. Mr. Herring has passed the Series 7 General Securities Representative Exam, administered by the Financial Industry Regulatory Authority, Inc. He holds a Bachelor of Arts degree in Management and Economics and a Master's of Business Administration from Georgia Institute of Technology Scheller College of Business.
- Bronwen Bastone
Bronwen Bastone，自2021年10月起担任Enfusion, Inc.首席人事官。在加入Enfusion之前，Bastone女士曾于2017年7月至2021年10月担任Exos Financial LLC的合伙人。Bastone女士还曾在布鲁克菲尔德资产管理、Cushman & Wakefield、Knight Capital和美林证券等机构的人力资源部门任职。Bastone女士拥有澳大利亚悉尼科技大学的工商管理硕士学位。
Bronwen Bastone,has been Enfusion, Inc. Chief People Officer since October 2021. Prior to joining Enfusion Ms. Bastone was a Partner at Exos Financial LLC from July 2017 to October 2021. Ms. Bastone has also held positions within HR at institutions such as Brookfield Asset Management, Cushman & Wakefield, Knight Capital and Merrill Lynch. Ms. Bastone holds an M.B.A. from the University of Technology, Sydney, Australia.- Bronwen Bastone，自2021年10月起担任Enfusion, Inc.首席人事官。在加入Enfusion之前，Bastone女士曾于2017年7月至2021年10月担任Exos Financial LLC的合伙人。Bastone女士还曾在布鲁克菲尔德资产管理、Cushman & Wakefield、Knight Capital和美林证券等机构的人力资源部门任职。Bastone女士拥有澳大利亚悉尼科技大学的工商管理硕士学位。
- Bronwen Bastone,has been Enfusion, Inc. Chief People Officer since October 2021. Prior to joining Enfusion Ms. Bastone was a Partner at Exos Financial LLC from July 2017 to October 2021. Ms. Bastone has also held positions within HR at institutions such as Brookfield Asset Management, Cushman & Wakefield, Knight Capital and Merrill Lynch. Ms. Bastone holds an M.B.A. from the University of Technology, Sydney, Australia.